PMID- 36381083
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221117
IS  - 1452-8258 (Print)
IS  - 1452-8266 (Electronic)
IS  - 1452-8266 (Linking)
VI  - 41
IP  - 4
DP  - 2022 Oct 15
TI  - The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in 
      retinoblastoma.
PG  - 497-505
LID - 10.5937/jomb0-34794 [doi]
AB  - BACKGROUND: This study was designed to investigate the abnormal expression of 
      plasma miR-592 and miR-217-3p in retinoblastoma (Rb) and explore the clinical 
      diagnostic value of their expression levels for Rb. METHODS: The 100 Rb patients 
      who came to Nanchang Hongdu Hospital of Traditional Chinese Medicine from January 
      2018 to January 2019 were selected as the Rb group, and 100 healthy patients who 
      came to the physical examination centre during the same period were selected as 
      the control group. Real-time fluorescence quantitative PCR (qRT-PCR) was used to 
      detect the expression levels of plasma miR-592 and miR-217-3p in all subjects; 
      analyse the relationship between plasma miR-592 and miR-217-3p levels and the 
      clinicopathological characteristics of Rb. Pearson correlation analysis evaluated 
      the relationship between plasma miR-592 and miR-217-3p levels and overall 
      survival. RESULTS: Plasma levels of miR-592 and miR-217-3p in the Rb group were 
      significantly higher than those in the control group (p<0.0001), and the 
      expression of miR-592 was significantly correlated with family genetic history (p 
      0.0001), tumour bias (p=0.0081), lymph node metastasis (p=0.0048) and 
      pathological grade (p=0.0025), and the expression of miR-217-3p was significantly 
      related to family genetic history (p 0.0001), optic nerve infiltration (p 
      0.0001), lymph node metastasis (p=0.0090), and pathological grade (p 0.0001). The 
      high expression of miR-592 and miR-217-3p presents a more serious pathological 
      manifestation of Rb, and the overall survival of patients is significantly 
      shortened with the increase of miR-592 (r=-0.2276, p=0.0052) and miR-217-3p 
      levels (r=-0.6461, p 0.0001). CONCLUSIONS: and miR-217-3p are highly expressed in 
      the plasma of Rb patients, and their elevated levels present severe pathological 
      manifestations of Rb and shortened overall survival, which is expected to become 
      biomarkers for clinical diagnosis of Rb.
CI  - 2022 Luo Jin Yan, Huang Bin Lin, Hu Qi Yu, Li Ru Jie, Jun Chen, Yuan Ling Mei, 
      Yuan Peng, published by CEON/CEES.
FAU - Yan, Luo Jin
AU  - Yan LJ
AD  - Nanchang Hongdu Hospital of Traditional Chinese Medicine, The Five Senses of 
      Chinese Medicine, Nanchang City, China.
FAU - Lin, Huang Bin
AU  - Lin HB
AD  - Jiangxi University of Traditional Chinese Medicine, The Five Senses of Chinese 
      Medicine, Nanchang City, China.
FAU - Yu, Hu Qi
AU  - Yu HQ
AD  - Nanchang Hongdu Hospital of Traditional Chinese Medicine, The Five Senses of 
      Chinese Medicine, Nanchang City, China.
FAU - Jie, Li Ru
AU  - Jie LR
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, The 
      Five Senses of Chinese Medicine, Nanchang City, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, The 
      Five Senses of Chinese Medicine, Nanchang City, China.
FAU - Mei, Yuan Ling
AU  - Mei YL
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, The 
      Five Senses of Chinese Medicine, Nanchang City, China.
FAU - Peng, Yuan
AU  - Peng Y
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, The 
      Five Senses of Chinese Medicine, Nanchang City, China.
LA  - eng
PT  - Journal Article
PL  - Serbia
TA  - J Med Biochem
JT  - Journal of medical biochemistry
JID - 101315490
PMC - PMC9618339
OTO - NOTNLM
OT  - correlation
OT  - miR-217-3p
OT  - miR-592
OT  - retinoblastoma
COIS- Conflict of Interest: The authors stated that they have no conflicts of interest 
      regarding the publication of this article.
EDAT- 2022/11/17 06:00
MHDA- 2022/11/17 06:01
PMCR- 2022/10/15
CRDT- 2022/11/16 02:47
PHST- 2021/12/07 00:00 [received]
PHST- 2022/01/21 00:00 [accepted]
PHST- 2022/11/16 02:47 [entrez]
PHST- 2022/11/17 06:00 [pubmed]
PHST- 2022/11/17 06:01 [medline]
PHST- 2022/10/15 00:00 [pmc-release]
AID - jomb-41-4-2204497Y [pii]
AID - 10.5937/jomb0-34794 [doi]
PST - ppublish
SO  - J Med Biochem. 2022 Oct 15;41(4):497-505. doi: 10.5937/jomb0-34794.